SXC enters definitive agreement to acquire MedMetrics

NewsGuard 100/100 Score

SXC Health Solutions Corp. ("SXC") (NASDAQ: SXCI, TSX: SXC), announced today it has entered into a definitive agreement to acquire substantially all of the assets of MedMetrics Health Partners, Inc. ("MedMetrics"), the full-service PBM subsidiary of Public Sector Partners, Inc. which is affiliated with a major medical school.

"We are very pleased to welcome MedMetrics and its employees into the SXC fold," said Mark Thierer, Chairman, President and CEO of SXC.  "We have worked with MedMetrics as a client and a partner over the past seven years; they began with SXC as a healthcare IT client and later expanded the relationship to include PBM services.  This transaction is in keeping with our strategy to acquire assets that currently utilize SXC's technology platform and can be easily integrated.  We look forward to leveraging our existing partnership and the strong MedMetrics footprint in the northeast to continue to grow the SXC business in that market."

"MedMetrics has had a long-term, collaborative relationship with SXC and coming together is a natural fit for both of us.  The strength of our relationship combined with the resources that SXC brings to the table will bring additional opportunities for our clients to improve care while benefiting from enhanced operational efficiencies," said Jim Hooley, Interim Managing Director of MedMetrics.

The acquisition is subject to various closing conditions and is expected to be completed during the second quarter of 2011.  MedMetrics manages approximately $200 million in annual drug spend and is accounted for in SXC's PBM segment.  When taking into account deal-related closing expenses and related amortization, the acquisition is not expected to have a material impact to 2011 fully-diluted GAAP EPS.

Source:

SXC HEALTH SOLUTIONS CORP.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds Epstein-Barr virus T-cells prevalent in early multiple sclerosis